TWI757229B - 用於治療微生物感染的化合物以及該化合物的用途 - Google Patents

用於治療微生物感染的化合物以及該化合物的用途 Download PDF

Info

Publication number
TWI757229B
TWI757229B TW104139459A TW104139459A TWI757229B TW I757229 B TWI757229 B TW I757229B TW 104139459 A TW104139459 A TW 104139459A TW 104139459 A TW104139459 A TW 104139459A TW I757229 B TWI757229 B TW I757229B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
nitrogen
compound
carbon
Prior art date
Application number
TW104139459A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625664A (zh
Inventor
布朗潘美拉
道森麥克
西莫諾維克蒙娜
布克斯史帝芬
杜波奇伊斯特
史坦威史蒂芬詹姆斯
威爾森安托內特
摩斯史蒂芬弗雷德里克
Original Assignee
美商斯佩羅治療學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1421020.7A external-priority patent/GB201421020D0/en
Priority claimed from GBGB1516059.1A external-priority patent/GB201516059D0/en
Application filed by 美商斯佩羅治療學股份有限公司 filed Critical 美商斯佩羅治療學股份有限公司
Publication of TW201625664A publication Critical patent/TW201625664A/zh
Application granted granted Critical
Publication of TWI757229B publication Critical patent/TWI757229B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104139459A 2014-11-26 2015-11-26 用於治療微生物感染的化合物以及該化合物的用途 TWI757229B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1421020.7A GB201421020D0 (en) 2014-11-26 2014-11-26 Compounds
GB1421020.7 2014-11-26
GBGB1516059.1A GB201516059D0 (en) 2015-09-10 2015-09-10 Compounds
GB1516059.1 2015-09-10

Publications (2)

Publication Number Publication Date
TW201625664A TW201625664A (zh) 2016-07-16
TWI757229B true TWI757229B (zh) 2022-03-11

Family

ID=54705181

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104139459A TWI757229B (zh) 2014-11-26 2015-11-26 用於治療微生物感染的化合物以及該化合物的用途

Country Status (8)

Country Link
US (2) US12146004B2 (https=)
EP (1) EP3224273A1 (https=)
JP (1) JP7349773B2 (https=)
CN (1) CN107108699A (https=)
AU (1) AU2015352440B2 (https=)
CA (1) CA2968902C (https=)
TW (1) TWI757229B (https=)
WO (1) WO2016083531A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146004B2 (en) * 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2018006063A1 (en) * 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
JP6975433B2 (ja) * 2016-12-16 2021-12-01 中国医学科学院医薬生物技術研究所 ポリミキシン誘導体及びその製造方法と応用
CN111527100A (zh) * 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
CN111559992B (zh) * 2020-05-29 2022-04-08 华中科技大学 一种2-芳基-γ-氨基丁酸衍生物的制备方法
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
WO2022206826A1 (zh) * 2021-03-31 2022-10-06 江苏奥赛康药业有限公司 一种多粘菌素衍生物的硫酸盐及其药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215677A1 (en) * 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
CN103946233A (zh) * 2011-11-18 2014-07-23 诺瓦克塔生物系统有限公司 多黏菌素衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (https=) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) * 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
KR102354902B1 (ko) 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
MX359104B (es) 2014-03-11 2018-09-14 New Pharma Licence Holdings Ltd Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
JP2017512818A (ja) * 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体
US12146004B2 (en) * 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2016166103A1 (en) 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
EP3356387B1 (en) 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
RS65128B1 (sr) 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215677A1 (en) * 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
CN103946233A (zh) * 2011-11-18 2014-07-23 诺瓦克塔生物系统有限公司 多黏菌素衍生物

Also Published As

Publication number Publication date
CA2968902C (en) 2023-08-29
US12146004B2 (en) 2024-11-19
JP7349773B2 (ja) 2023-09-25
CN107108699A (zh) 2017-08-29
TW201625664A (zh) 2016-07-16
JP2017538692A (ja) 2017-12-28
WO2016083531A1 (en) 2016-06-02
AU2015352440A1 (en) 2017-06-29
US20230340026A1 (en) 2023-10-26
US20180030092A1 (en) 2018-02-01
AU2015352440B2 (en) 2020-02-06
EP3224273A1 (en) 2017-10-04
CA2968902A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
TWI757229B (zh) 用於治療微生物感染的化合物以及該化合物的用途
ES2923762T3 (es) Derivados de polimixina y su uso en terapia combinado junto con diferentes antibióticos
CN106232617B (zh) 多粘菌素衍生物及其在与不同抗生素的联合疗法中的用途
US20150031602A1 (en) Compounds
ES2971732T3 (es) Compuestos
EA047835B1 (ru) Соединения
BR112016020998B1 (pt) Compostos derivados de polimixina, composições farmacêuticas compreendedo os ditos compostos e usos terapêuticos dos mesmos

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees